retatrutide benefits clinical trials (“reta”) is an experimental weight-loss drug currently in Phase 3 trials. It's a once-weekly injection similar to Ozempic and Mounjaro—but more powerful. The reason comes down to how it works Triple hormone receptor agonist retatrutide

Specificity of insulin and insulin-like growth factor I receptors investigated using chimeric mini-receptors

Cardiovascular and non- cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta- analysis of randomized controlled cardiovascular outcome trials

Per HumeCare's own materials, Hume Care has no affiliation with Novo Nordisk A/S, Eli Lilly and Company, or Amylin Pharmaceuticals, Inc

The newsletter also includes 25 question and answers addressing the following topics: Insertion into Ventricular Septum Extraction of Omentum and Mesentery Transfer of Bladder Resection of Prostate with Intact Capsule Dementia and Hypothyroidism Adverse Effects of Injectable Non-Insulin Antidiabetic Drug Long-Term Use of Semaglutide or Tirzepatide Gastroparesis Due to Tirzepatide Insertion of Two Impella Devices During Separate Operative Episodes Starvation Ketoacidosis Cesarean Delivery Without a Current Medical Indication Cesarean Delivery Due to History of Shoulder Dystocia North-South Syndrome (NSS) Liver Cirrhosis Due to Non-Alcoholic Steatohepatitis (NASH) Liver Cirrhosis Due to Hepatitis C Acute Kidney Failure Due to Rhabdomyolysis Low Back Pain Ruptured Ovarian Cyst Acute Myocarditis Due to Systemic Lupus Erythematosus Sepsis Due to Urinary Tract Infection (UTI) Thrombocytopenia and Disseminated Intravascular Coagulation (DIC) Correction: NSTEMI Due to Graft Thrombosis Clarification: Interbody Fusion New Technology Device Value Clarification: Laminoplasty Internal Fixation Device Terms to Know Review the following terms to help understand the modifications that go into effect April 1: Those are just the highlights